Skip to main content

Cenix, Janssen Expand siRNA Delivery Collaboration

Premium

Cenix BioScience said this week that it has signed a collaboration and technology license agreement with Belgium-based Janssen Research and Development to co-develop Cenix's DARE siRNA delivery technology to improve the in vivo applicability of experiments that use the gene-silencing molecules.

According to Cenix, the deal represents an expansion of an ongoing partnership with Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

Cenix noted that certain of the technologies developed through the arrangement are expected to be useful for therapeutic siRNA delivery, as well, and will be fully owned by Cenix.

Specific terms of the arrangement were not disclosed.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.